American Century Companies Inc. Has $1.09 Billion Stock Holdings in Johnson & Johnson (NYSE:JNJ)

American Century Companies Inc. increased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,518,301 shares of the company's stock after purchasing an additional 286,239 shares during the quarter. Johnson & Johnson accounts for about 0.6% of American Century Companies Inc.'s investment portfolio, making the stock its 16th largest holding. American Century Companies Inc. owned about 0.31% of Johnson & Johnson worth $1,087,297,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. IFS Advisors LLC grew its position in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after buying an additional 100 shares during the last quarter. RPg Family Wealth Advisory LLC acquired a new position in Johnson & Johnson in the third quarter valued at approximately $35,000. Bay Harbor Wealth Management LLC bought a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $32,000. Runnymede Capital Advisors Inc. acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $38,000. Finally, NewSquare Capital LLC lifted its holdings in shares of Johnson & Johnson by 145.8% in the 4th quarter. NewSquare Capital LLC now owns 290 shares of the company's stock worth $42,000 after purchasing an additional 172 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the business's stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company's stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Remove Ads

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on JNJ shares. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research report on Monday, March 10th. StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 25th. Raymond James cut their price target on Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating on the stock in a report on Thursday, January 23rd. Finally, Citigroup decreased their price objective on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a report on Wednesday, December 11th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and an average target price of $171.33.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded down $2.15 during trading hours on Tuesday, hitting $161.14. 7,455,754 shares of the company's stock traded hands, compared to its average volume of 7,088,162. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The company's fifty day simple moving average is $157.37 and its two-hundred day simple moving average is $156.16. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a market cap of $388.32 billion, a price-to-earnings ratio of 24.23, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm's quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.29 earnings per share. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were given a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.08%. Johnson & Johnson's dividend payout ratio (DPR) is 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.